According to the Zhitong Finance App, Shanghai Rice (002252.SZ) announced that the company plans to acquire 100% of the shares of Boehringer Ingelheim Biopharmaceutical (China) Co., Ltd. (the “Target Company”) held by Boehringer Ingelheim (China) Investment Co., Ltd. in cash. The estimated purchase price is no more than 20 million yuan. After the transaction is completed, the target company will become a wholly-owned subsidiary of the company.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.